This invention generally relates to muscarinic receptor antagonists of
formula (I) which are useful, among other uses, for the treatment of
various diseases of the respiratory, urinary and gastrointestinal systems
mediated through muscarinic receptors. Specifically, the invention
relates to derivatives of azabicyclo compounds, including, for example,
6-substituted azabicyclo[3.1.0]hexanes, as well as pharmaceutical
compositions containing such compounds and methods of treating diseases
mediated through muscarinic receptors.